SGLT-2 inhibitors are a new class of anti-hyperglycemic agents that have been approved for the treatment of type 2 diabetes mellitus (T2DM) (Yeğit et al., 2023). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.